Brilinta

(Ticagrelor)

ApprovedSmall molecule

Ticagrelor is used to prevent blood clots and reduce the risk of heart attack or stroke in people with acute coronary syndrome (a type of severe chest pain or heart problem). It works by making blood less sticky so clots are less likely to form.[2] Brilinta is currently approved and in use across 34 indications[4].[1]

Brilinta is one of 489 small molecule programs targeting Acute Coronary Syndrome. It is currently in Approved.

Indications

299

Total Trials

Active Trials

488

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Acute Coronary SyndromeTerminated

AtherosclerosisCompleted

Angina PectorisActive, not recruiting

InteractionNot yet recruiting

Thrombotic DiseaseActive, not recruiting

Peripheral Vascular DiseaseActive, not recruiting

Recurrent ThrombophlebitisActive, not recruiting

Peripheral Arterial DiseaseApproved

Brain AneurysmApproved

Rheumatoid ArthritisActive, not recruiting

Acute Coronary SyndromeApproved

Terminated

AtherosclerosisApproved

Completed

Angina PectorisApproved

Active, not recruiting

InteractionPhase 1

Not yet recruiting

Thrombotic DiseaseApproved

Active, not recruiting

Peripheral Vascular DiseaseApproved

Active, not recruiting

Recurrent ThrombophlebitisApproved

Active, not recruiting

Peripheral Arterial DiseaseApproved

Approved

Brain AneurysmApproved

Approved

Rheumatoid ArthritisApproved

Active, not recruiting

Showing 10 of 31 indications

Competition

Competitive Landscape

181 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Brilinta

AstraZeneca

Approved

1 2

Actos

Takeda

Preclinical

2 3

Celexa

AbbVie

Preclinical

1 4

Voltaren

Cataflam

Plaquenil

Velcade

SShilpa Grover, MD, MPH

Preclinical

2 8

Vancocin

HHikma Pharmaceuticals LLC

Preclinical

1 9

Pneumococcal Conjugate Vaccine

Novartis

Preclinical

1 10

Disalcid

JJoslin Diabetes Center

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Acute Coronary Syndrome

NCT04240834

Post-ApprovalRecruiting

Dual Antiplatelet Therapy

NCT06691191

Q1 2027

Phase 1Not yet recruiting

Interaction

NCT07438886

Q2 2027

Post-ApprovalRecruiting

Percutaneous Coronary Intervention

NCT06228456

Q3 2027

Phase 3Recruiting

Atherosclerosis

NCT05476991

Clinical

Trials by Indication[1]

Acute Coronary Syndrome22 trials

Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome

Completed·TThe University of Hong Kong·Phase 4·NCT01994941·133 enrolled

Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes

Completed·IIHF GmbH - Institut für Herzinfarktforschung··NCT02265068·700 enrolled

Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome

Unknown status·CCollegium Medicum w Bydgoszczy·Phase 3·NCT04718025·4,500 enrolled

Show 19 more trials

Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)

Completed·—·Phase 3·NCT02944123·120 enrolled

Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes

Completed·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 4·NCT04057300·1,038 enrolled

Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes

Completed·SSeung-Jung Park·Phase 2·NCT02319941·65 enrolled

ADHerence of ticagrelOr in Real World Patients With aCute Coronary Syndrome

Completed·FFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS··NCT03129867·480 enrolled

A sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients

Recruiting·SShanghai Tong Ren Hospital·Phase 4·NCT04307511·40 enrolled

Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.

Terminated· AstraZeneca logo

AstraZeneca·Phase 4·NCT02052635·34 enrolled

Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01294462·801 enrolled

IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome

Recruiting·SShanghai Zhongshan Hospital·Phase 4·NCT06451198·2,846 enrolled

Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT01603082·343 enrolled

Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome

Completed·UUniversity Hospital, Ghent·Phase 4·NCT02341729·40 enrolled

Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Completed·UUniversity of Patras·Phase 4·NCT01642966·56 enrolled

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT02293395·3,037 enrolled

Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome

Unknown status·AAndalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud··NCT04630288·1,900 enrolled

The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome

Completed·LLiverpool University Hospitals NHS Foundation Trust··NCT02484924·5,225 enrolled

TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.

Completed·AAssistance Publique Hopitaux De Marseille·Phase 3·NCT03357874·259 enrolled

Comparison of Antiplatelet Effect of Ticagrelor vs Tirofiban in Patients With Non-ST Elevation Acute Coronary Syndrome

Unknown status·PPusan National University Yangsan Hospital·Phase 3·NCT01660373·100 enrolled

LOwer Maintenance Dose TICagrelor in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention

Unknown status·—·Phase 4·NCT04060914·225 enrolled

Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity

Unknown status·FFirst Affiliated Hospital of Harbin Medical University·Phase 2/3·NCT03062462·80 enrolled

Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention

Recruiting·FFu Wai Hospital, Beijing, China·Phase 4·NCT04240834·1,220 enrolled

Clopidogrel13 trials

Efficacy of Ticagrelor vs Clopidogrel in High-risk NSTE-ACS Patients Undergoing Early PCI

Unknown status·RRenJi Hospital·Phase 4·NCT02201667·444 enrolled

Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During PCI: an OCT Study

Withdrawn·MMassachusetts General Hospital·Phase 4·NCT01826175

Clopidogrel And Ticagrelor in Healthy Subjects

Completed·—·Phase 3·NCT02086903·12 enrolled

Show 10 more trials

A Clinical Study of Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patient

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 3·NCT01757262

Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With STEMI Undergoing Primary PCI

Unknown status·TTaipei Veterans General Hospital, Taiwan·Phase 4·NCT02792712·200 enrolled

High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients

Completed·UUniversity of Roma La Sapienza·Phase 3·NCT01543932·81 enrolled

The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man

Completed·MMedical University of Vienna·Phase 2·NCT02120092·89 enrolled

TIMES: Ticagrelor vs. Placebo/ Clopidogrel With Aspirin in Anterior STEMI Patients Treated With Primary PCI

Unknown status·PPapworth Hospital NHS Foundation Trust·Phase 2·NCT03145194·140 enrolled

Ticagrelor vs. Clopidogrel in Post PCI Patients

Completed·SShiraz University of Medical Sciences·N/A·NCT05858918·476 enrolled

Ticagrelor vs Clopidogrel Effect on MFR in CAD Population

Completed·OOttawa Heart Institute Research Corporation·Phase 2/3·NCT01894789·36 enrolled

Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT02925923·100 enrolled

Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel

Unknown status·RRabin Medical Center·Phase 4·NCT01643031·500 enrolled

COmparison of the Pharmacodynamics and Pharmacokinetics Ticagrelor Versus Clopidogrel in Patients With CKD and NSTE-ACS

Unknown status·SShenyang Northern Hospital·Phase 4·NCT02578537·60 enrolled

Myocardial Infarction10 trials

Effect of Diabetes and Hepatic Enzymes Mutation on Clopidogrel VS Ticagrelor Activity in Myocardial Infarction (MI) Patients Undergoing Primary Percutaneous Coronary Intervention (PCI)

Completed·—··NCT03613857·1,022 enrolled

Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction

Terminated·—·Phase 3·NCT02075125·39 enrolled

Effectiveness of Lower Maintenance Dose of Ticagrelor Early After Myocardial Infarction (ELECTRA) Pilot Study

Completed·CCollegium Medicum w Bydgoszczy·Phase 3·NCT03251859·52 enrolled

Show 7 more trials

Low Dose Ticagrelor Versus Low Dose Prasugrel in Patients With Prior Myocardial Infarction

Completed·—·Phase 4·NCT03387826·20 enrolled

Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

Completed·UUniversity of Florida·Phase 4·NCT02545933·130 enrolled

Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)

Completed·UUniversity of Patras·Phase 4·NCT01575795·83 enrolled

Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)

Completed·UUniversity of Patras·Phase 4·NCT01463163·50 enrolled

Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.

Withdrawn·RRegion Skane·Phase 3·NCT04069234

Daily Variability of Platelet Aggregation in Patients With Myocardial Infarction Treated With Prasugrel and Ticagrelor

Completed·CCollegium Medicum w Bydgoszczy··NCT03454841·73 enrolled

PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus

Completed·GGennaro Sardella·Phase 3·NCT01531114·50 enrolled

Coronary Artery Disease7 trials

Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease

Completed·UUniversity of Florida·N/A·NCT01852175·110 enrolled

Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease

Completed·FFirst Affiliated Hospital of Harbin Medical University·Phase 4·NCT04001894·50 enrolled

The Effects of loW Dose tIcagrelor on Platelet Function Testing in Patients With Stable Coronary arTery Disease

Completed·TThe University of The West Indies·Phase 1/2·NCT04206176·25 enrolled

Show 4 more trials

Differential Effect of Ticagrelor Versus Prasugrel Maintenance Dose on Endothelial Function of Peripheral Vessels in Patients With Coronary Artery Disease

Completed·UUniversity of Patras·Phase 4·NCT01957540·22 enrolled

A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT05093790·58 enrolled

Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease

Completed·UUniversity of Florida·Phase 4·NCT04006288·90 enrolled

Effects of Different Doses of Ticagrelor on Platelet Aggregation and Endothelial Function in Diabetic Patients With Stable Coronary Artery Disease

Unknown status·FFirst Affiliated Hospital of Harbin Medical University·Phase 2/3·NCT02889549·60 enrolled

Endothelial Function6 trials

ComparisoN of ticAgrelor vs. Clopidogrel in endoTHeliAl Function of COPD patieNts

Completed·UUniversity Hospital of Ferrara·Phase 2·NCT02519608·44 enrolled

The Effect of Ticagrelor or Clopidogrel on Endothelial Function During Acute and Chronic Treatment

Completed·MMichael Wolzt, Prof. MD·Phase 4·NCT02580149·24 enrolled

Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH)

Completed·EErasmus Medical Center·Phase 4·NCT02587260·54 enrolled

Show 3 more trials

Ticagrelor and Endothelial Function

Unknown status·HHotel Dieu de France Hospital·Phase 4·NCT02261922·20 enrolled

The Effect of Ticagrelor With or Without Atorvastatin on Endothelial Function in Healthy Males

Completed·MMedical University of Vienna·Phase 4·NCT02910778·32 enrolled

Effect of Ticagrelor on Endothelial Function

Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 3·NCT01805596·45 enrolled

80 more indications

Ischemic stroke6 trials

Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke

Completed·KKafrelsheikh University·Phase 3·NCT06120725·580 enrolled

Efficacy of Ticagrelor Plus Aspirin in Mild Non-cardioembolic Ischemic Stroke

Completed·MMazandaran University of Medical Sciences·Phase 3·NCT04738097·90 enrolled

Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke

Recruiting·KKafrelsheikh University·Phase 3·NCT06202755·580 enrolled

Show 3 more trials

Ticagrelor Versus Cilostazol in Ischemic Stroke

Recruiting·KKafrelsheikh University·Phase 3·NCT06561867·900 enrolled

Ticagrelor Versus Clopidogrel in Ischemic Stroke

Completed·KKafrelsheikh University·Phase 3·NCT05553613·900 enrolled

Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA

Recruiting·KKafrelsheikh University·Phase 3·NCT06196047·900 enrolled

Stroke6 trials

Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA

Recruiting·KKafrelsheikh University·Phase 3·NCT06591377·900 enrolled

Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA

Recruiting·KKafrelsheikh University·Phase 3·NCT06591390·900 enrolled

Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA

Recruiting·KKafrelsheikh University·Phase 3·NCT06591312·900 enrolled

Show 3 more trials

Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA

Recruiting·KKafrelsheikh University·Phase 3·NCT06591338·900 enrolled

THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT03354429·11,016 enrolled

[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01994720·13,307 enrolled

Antiplatelet5 trials

A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00642811·98 enrolled

Replication of the ISAR-REACT 5 Antiplatelet Trial in Healthcare Claims Data

Completed·—··NCT05086081·28,389 enrolled

A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00528411·123 enrolled

Show 2 more trials

Replication of the PLATO Antiplatelet Trial in Healthcare Claims Data

Completed·—··NCT04237935·27,960 enrolled

Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients

Completed·—·Phase 4·NCT01706510·28 enrolled

Platelet Reactivity4 trials

A Study of the Effect of Epinephrine on Platelet Reactivity in Subjects Treated With Ticagrelor

Completed·VVastra Gotaland Region·Phase 1·NCT03441412·10 enrolled

Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation

Completed·AAndres Iñiguez Romo·Phase 4·NCT04331145·40 enrolled

Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After PCI

Withdrawn·NNanjing First Hospital, Nanjing Medical University·Phase 3·NCT03078465

Show 1 more trial

Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor

Unknown status·LLifeBridge Health·Phase 4·NCT01869309·400 enrolled

Percutaneous Coronary Intervention4 trials

Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention

Recruiting·UUniversity of Florida·Phase 4·NCT06228456·50 enrolled

Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention

Terminated·TThe Guthrie Clinic·Phase 4·NCT03476369·45 enrolled

Ticagrelor and Intracoronary Morphine in Patients Undergoing Primary Percutaneous Coronary Intervention

Unknown status·HHyeon-Cheol Gwon·Phase 2·NCT01738100·100 enrolled

Show 1 more trial

Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention

Completed·TThe First Affiliated Hospital of Dalian Medical University··NCT04999293·1,505 enrolled

Platelet Aggregation3 trials

Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or Prasugrel

Completed·UUniversity of Sao Paulo·Phase 4·NCT05247385·87 enrolled

Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD

Unknown status·FFirst Affiliated Hospital of Harbin Medical University·Phase 4·NCT03614832·100 enrolled

Arachidonic Acid-induced Platelet Aggregation Rate in Patients With Stable CAD Treated With Ticagrelor Monotherapy

Completed·YYong Huo·Phase 4·NCT02219412·70 enrolled

Injury3 trials

Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery

Terminated·TThe Cleveland Clinic·Phase 4·NCT02291419·6 enrolled

DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury

Completed·UUniversity of Edinburgh·Phase 2/3·NCT02110303·220 enrolled

Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI

Completed·AAORTICA Group·N/A·NCT03435133·61 enrolled

STEMI3 trials

Chewing Versus Traditional Oral Administration of Ticagrelor in STEMI Patients

Completed·SSheba Medical Center·Phase 4·NCT02725099·50 enrolled

Early Versus Late Loading of Ticagrelol in Patients With STEMI

Unknown status·—··NCT04267224·800 enrolled

High Ticagrelor Loading Dose in STEMI

Completed·UUniversity of Florida·Phase 2·NCT01898442·52 enrolled

Interaction3 trials

Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers

Not yet recruiting·AAdvenchen Laboratories Nanjing Ltd.·Phase 1·NCT07438886·16 enrolled

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

Completed·VViatris Innovation GmbH·Phase 1·NCT03430661·77 enrolled

Evaluation of the Drug-drug Interaction Between Ticagrelor and Venlafaxine When Taken Together in Healthy Volunteers

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01350921·22 enrolled

Dual Antiplatelet Therapy3 trials

A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)

Terminated·OOttawa Heart Institute Research Corporation·Phase 4·NCT03224923·5 enrolled

Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS

Unknown status·EEast and North Hertfordshire NHS Trust·Phase 4·NCT03775746·150 enrolled

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

Recruiting·UUniversity of Florida·Phase 4·NCT06691191·48 enrolled

Acute Myocardial Infarction3 trials

Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction

Completed·FFaculty Hospital Kralovske Vinohrady·Phase 4·NCT02808767·1,226 enrolled

Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction

Completed·MMedical University of Warsaw·Phase 4·NCT02931045·60 enrolled

Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction

Completed·FFaculty Hospital Kralovske Vinohrady·Phase 4·NCT03551964·605 enrolled

Thrombolysis3 trials

Ticagrelor for PCI Post Thrombolysis

Completed·UUnity Health Toronto·Phase 3·NCT01930591·140 enrolled

Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis

Withdrawn·—·Phase 4·NCT02048085

Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis

Completed·FFederal University of São Paulo·Phase 4·NCT02215993·50 enrolled

Function2 trials

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study

Completed·UUniversity of Florida·Phase 4·NCT03489863·14 enrolled

A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:

Completed·UUniversity of Florida·Phase 4·NCT02065479·65 enrolled

Cardiac Arrest2 trials

Add-on Cangrelor in STEMI-triggered Cardiac Arrest

Unknown status·MMedical University of Vienna·Phase 4·NCT03273075·60 enrolled

Antiplatelet Therapy After Cardiac Arrest

Completed·UUniversity Medical Centre Ljubljana·Phase 4·NCT02224274·57 enrolled

Tics2 trials

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04588727·103 enrolled

Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects

Completed·TTianjin Institute of Pharmaceutical Research Co., Ltd·Phase 1·NCT06584812·14 enrolled

Antithrombotic2 trials

DUAL Antithrombotic Therapy in Patients With AF and ACS

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04023630·4,000 enrolled

Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI

Recruiting·MMedical University of Gdansk·Phase 4·NCT04695106·2,230 enrolled

MPA2 trials

A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03126695·44 enrolled

Impact of Ticagrelor Re-load on Pharmacodynamic Profiles

Completed·UUniversity of Florida·N/A·NCT01731041·60 enrolled

Complication2 trials

Comparison of CABG Related Bleeding Complications in Patients Treated With Ticagrelor or Clopidogrel

Completed·—··NCT04431349·1,097 enrolled

Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.

Active, not recruiting·PPetrovsky National Research Centre of Surgery··NCT07358416·500 enrolled

CABG2 trials

One-Month DAPT in CABG Patients

Recruiting·WWeill Medical College of Cornell University·Phase 3·NCT05997693·700 enrolled

Optimizing Timing of CABG in Patients Presenting With ACS and Treated With Ticagrelor

Unknown status·UUnity Health Toronto·Phase 4·NCT02627521·260 enrolled

P2Y12 Inhibitor2 trials

Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02617290·1,900 enrolled

P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold

Terminated·SSamsung Medical Center·Phase 4·NCT03119012·25 enrolled

Pneumonia2 trials

Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor

Completed·UUniversity of Kentucky·Phase 1·NCT01883869·60 enrolled

Ticagrelor in Severe Community Acquired Pneumonia

Terminated·GGordon Bernard·Phase 2·NCT01998399·25 enrolled

Atrial Fibrillation2 trials

Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT02866175·1,506 enrolled

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01830543·2,124 enrolled

Antiplatelet Therapy2 trials

Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis

Completed·—·Phase 4·NCT02053909·250 enrolled

Tailored Antiplatelet Therapy Following PCI

Completed·MMayo Clinic·Phase 4·NCT01742117·5,276 enrolled

Platelet Function2 trials

Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing

Unknown status·DDeutsches Herzzentrum Muenchen·Phase 4·NCT01456364·70 enrolled

The ACS Ethnicity Platelet Function Study

Completed·MMedstar Health Research Institute··NCT01829659·4 enrolled

Effectiveness2 trials

Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD

Unknown status·NNorth Texas Veterans Healthcare System·Phase 4·NCT03150667·220 enrolled

Safety and Effectiveness of Ticagrelor in Patients Undergoing Carotid Stenting

Unknown status·—·Phase 1·NCT04091074·26 enrolled

Coronary Artery Bypass2 trials

A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting

Completed·—·Phase 4·NCT02330640·137 enrolled

Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery

Completed·CCardiology Research UBC·Phase 4·NCT01373411·70 enrolled

Abdominal Aortic Aneurysm1 trial

The Efficacy of Ticagrelor on Abdominal Aortic Aneurysm (AAA) Expansion

Completed·UUppsala University·Phase 2·NCT02070653·145 enrolled

Diabetes1 trial

Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes

Completed·UUniversity of Florida·N/A·NCT01852214·50 enrolled

Dialysis Patients1 trial

Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02022748·27 enrolled

Endothelial Dysfunction1 trial

Effect of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation

Unknown status·KKiyuk Chang·Phase 4·NCT02379676·38 enrolled

LAM1 trial

Ticagrelor and Anti-inflammatory Effects

Unknown status·KKyunghee University Medical Center·Phase 3·NCT02406911·25 enrolled

Completed·UUniversity of Florida·N/A·NCT02016170·82 enrolled

Randomized Controlled Trial1 trial

TADCLOT- a Double Blind Randomized Controlled Trial

Completed·NNational Institute of Cardiovascular Diseases, Pakistan·Phase 3·NCT06318481·2,200 enrolled

Atherosclerosis1 trial

Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05476991·2,800 enrolled

TED1 trial

In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients

Completed·UUniversity of Florida·N/A·NCT02081443·60 enrolled

Platelet Inhibition1 trial

Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS

Completed·FFederico II University·Phase 3·NCT04739384·50 enrolled

Optical Coherence Tomography1 trial

Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy

Completed·—·Phase 2·NCT04766437·75 enrolled

Monotherapy1 trial

Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of ACS

Completed·TThe University of Hong Kong·Phase 4·NCT03881943·200 enrolled

ST Elevation Myocardial Infarction1 trial

Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis

Completed·HHospital do Coracao·Phase 3·NCT02298088·3,799 enrolled

Type 2 Diabetes Mellitus1 trial

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01991795·19,271 enrolled

Thrombosis1 trial

Ticagrelor in Post-transplant Patients With Pediatric Hepatic Artery Thrombosis (HAT)

Unknown status·RRenJi Hospital·Phase 3·NCT04946929·50 enrolled

Oral Anticoagulation1 trial

Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI

Completed·UUniversity of Florida·Phase 4·NCT04483583·81 enrolled

Chronic Kidney Disease1 trial

Chronic Kidney Disease (CKD) Platelet Study

Completed·UUniversity of Arkansas·Phase 3·NCT03649711·76 enrolled

Age1 trial

Optimal Dosage of Ticagrelor in Korean Patients With AMI

Unknown status·—·Phase 4·NCT05210595·120 enrolled

Vascular Disease1 trial

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01225562·21,379 enrolled

Angina Pectoris1 trial

Efficacy and Safety of Low Dose Ticagrelor in Patients With Unstable Angina Pectoris After Coronary Stent Implantation

Unknown status·XXiaofan Wu·Phase 4·NCT03620760·2,036 enrolled

Aortic Stenosis1 trial

Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)

Completed·UUniversity Hospitals Cleveland Medical Center·Phase 4·NCT02486367·60 enrolled

Intensive Care Unit1 trial

High "on Treatment" Platelet Reactivity in the Intensive Care Unit

Unknown status·MMedical University of Vienna·Phase 2·NCT02285751·200 enrolled

Arterial Stiffness1 trial

Compare Ticagrelor vs Clopidogrel on the Reduction of Arterial Stiffness and Wave Reflectionsin Patients With CAD.

Completed·HHellenic Cardiovascular Research Society·Phase 2·NCT02071212·120 enrolled

Statin1 trial

A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT06554821·28 enrolled

Microcirculation1 trial

Comparing Ticagrelor Versus Clopidogrel on Microcirculation

Completed·—·N/A·NCT02618733·120 enrolled

Prevention1 trial

Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG

Terminated·DDeutsches Herzzentrum Muenchen·Phase 3·NCT01755520·1,893 enrolled

Sickle Cell Disease1 trial

PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4)

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03492931·21 enrolled

Aneurysm1 trial

Ticagrelor vs Clopidogrel for Platelet Inhibition in Stenting for Cerebral Aneurysm

Completed·FFondation Ophtalmologique Adolphe de Rothschild·Phase 3·NCT02675205·100 enrolled

Intraoperative1 trial

Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel

Unknown status·YYongjian Wu·Phase 4·NCT02513004·60 enrolled

Ischemia1 trial

Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia

Terminated·TThe Cleveland Clinic·Phase 2/3·NCT02230527·46 enrolled

Type 2 Diabetes1 trial

Clopidogrel Versus Ticagrelor in Type-2 Diabetes

Completed·—·Phase 4·NCT02742987·42 enrolled

Oral1 trial

The Effect of IV Cangrelor and Oral Ticagrelor Study

Completed·TThe Royal Wolverhampton Hospitals NHS Trust·Phase 4·NCT02733341·100 enrolled

Infusion1 trial

Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT01919723·70 enrolled

RCT1 trial

Ticagrelor vs. Prasugrel Effects on Infarct Size

Withdrawn·YYochai Birnbaum·Phase 2·NCT02507323

Trial1 trial

Platelet Sub-study of the TWILIGHT Trial

Completed·JJuan Badimon··NCT04001374·40 enrolled

Treatment1 trial

Paradigm Shift in the Treatment of Patients With ACS

Completed·YYu Bo·Phase 4·NCT02041650·250 enrolled

Ventricular Function1 trial

A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study

Completed·HHellenic Cardiovascular Research Society·Phase 3·NCT02429271·336 enrolled

ART1 trial

Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS

Terminated·—·Phase 4·NCT02071966·55 enrolled

Efficacy and Safety1 trial

Efficacy and Safety Study of Ticagrelor

Unknown status·GGeneral Hospital of Chinese Armed Police Forces·Phase 3·NCT01812330·180 enrolled

Aspirin1 trial

GM03 - Platelet RNA Signatures of Aspirin

Completed·—·Phase 1·NCT05278637·135 enrolled

Peripheral Artery Disease1 trial

Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes

Completed·IIcahn School of Medicine at Mount Sinai·Phase 3·NCT02325466·70 enrolled

Immune Response1 trial

The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin

Completed·SSheffield Teaching Hospitals NHS Foundation Trust·Phase 4·NCT03869268·72 enrolled

Cardiovascular Disease1 trial

Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)

Completed·NNewcastle-upon-Tyne Hospitals NHS Trust·Phase 2·NCT03487406·120 enrolled

Endotoxemia1 trial

Ticagrelor in Human Endotoxemia Response to Human Endotoxemia

Completed·RRadboud University Medical Center·N/A·NCT02612480·40 enrolled

Coronary Artery Lesions1 trial

Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions

Unknown status·XXijing Hospital·N/A·NCT05209412·370 enrolled

Stent Implantation1 trial

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Completed·EECRI bv·Phase 3·NCT01813435·15,991 enrolled

Low Molecular Weight Heparin1 trial

The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI

Unknown status·—·Phase 4·NCT02658838·300 enrolled

Platelet Transfusion1 trial

Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01744288·258 enrolled

Atherosclerotic Plaque1 trial

Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation

Completed·CCHEOL WHAN LEE, M.D., Ph.D·Phase 4·NCT01905566·50 enrolled

Cholesterol1 trial

KF2019#1-trial: Effects of a Thrombocyte Inhibitor on a Cholesterol-lowering Drug

Unknown status·HHelsinki University Central Hospital·Phase 1·NCT05373277·10 enrolled

Inflammation1 trial

The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation

Withdrawn·—·Phase 4·NCT02626169

Unspecified15 trials

Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina

Unknown status·SSecond Xiangya Hospital of Central South University·Phase 4·NCT02284048·140 enrolled

A Pharmacodynamic Study With Ticagrelor in African American Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT01523392·50 enrolled

Ticagrelor Administered as Standard Tablet or Orodispersible Formulation

Completed·AAzienda Ospedaliero Universitaria di Sassari·Phase 3·NCT03822377·130 enrolled

Show 12 more trials

De-escalation of Ticagrelor in Post PPCI

Unknown status·—·Phase 1/2·NCT05831462·400 enrolled

ADHERE-S (NIS Brilique)

Completed· AstraZeneca logo

AstraZeneca··NCT03444012·269 enrolled

A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients

Unknown status·SShanghai Tong Ren Hospital·Phase 4·NCT04255602·2,120 enrolled

Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION)

Unknown status·GGyeongsang National University Hospital·Phase 4·NCT04734353·492 enrolled

Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence

Completed·—·Phase 3·NCT05474053·29 enrolled

Effect of Ticagrelor on Fractional Flow Reserve

Completed·UUniversity of Patras·Phase 4·NCT02108808·76 enrolled

NIRS Ticagrelor Evaluation

Completed·MMedstar Health Research Institute·Phase 4·NCT02282332·30 enrolled

Reversal of the Anti-platelet Effects of Ticagrelor

Completed·TThe First Affiliated Hospital with Nanjing Medical University·Phase 4·NCT02383771·64 enrolled

A Pharmacodynamic Study With Ticagrelor in Hispanic Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT01523366·53 enrolled

Chewed Versus Integral Pill of Ticagrelor

Completed·WWake Forest University Health Sciences·Phase 4·NCT03708588·112 enrolled

Τicagrelor Versus Prasugrel in Diabetic Patients: a Pharmacodynamic Study

Completed·UUniversity of Patras·Phase 4·NCT01642940·30 enrolled

Cangrelor Ticagrelor Transition Study

Completed· Novartis logo

Novartis·Phase 2·NCT01766466·12 enrolled

Regulatory

FDA Approval Timeline[5]

Jul 20, 2011

BRILINTA

NDA NDA022433

Nov 9, 2012

BRILINTA

NDA NDA022433

Dec 5, 2012

BRILINTA

NDA NDA022433

Jan 24, 2013

BRILINTA

NDA NDA022433

Mar 29, 2013

BRILINTA

NDA NDA022433

Oct 30, 2013

BRILINTA

NDA NDA022433

Dec 13, 2013

BRILINTA

NDA NDA022433

Mar 7, 2014

BRILINTA

NDA NDA022433

Jul 18, 2014

BRILINTA

NDA NDA022433

Mar 26, 2015

BRILINTA

NDA NDA022433

Jun 24, 2015

BRILINTA

NDA NDA022433

Sep 3, 2015

BRILINTA

NDA NDA022433

Sep 3, 2015

BRILINTA

NDA NDA022433

Sep 16, 2015

BRILINTA

NDA NDA022433

Sep 21, 2015

BRILINTA

NDA NDA022433

Jul 22, 2016

BRILINTA

NDA NDA022433

Aug 11, 2016

BRILINTA

NDA NDA022433

Sep 23, 2016

BRILINTA

NDA NDA022433

Mar 9, 2018

BRILINTA

NDA NDA022433

Apr 3, 2019

BRILINTA

NDA NDA022433

Oct 24, 2019

BRILINTA

NDA NDA022433

May 28, 2020

BRILINTA

NDA NDA022433

Sep 15, 2020

BRILINTA

NDA NDA022433

Nov 5, 2020

BRILINTA

NDA NDA022433

Feb 17, 2021

BRILINTA

NDA NDA022433

Aug 10, 2021

BRILINTA

NDA NDA022433

May 9, 2022

BRILINTA

NDA NDA022433

Mar 22, 2024

BRILINTA

NDA NDA022433

Nov 4, 2024

BRILINTA

NDA NDA022433

May 7, 2026

BRILINTA

NDA NDA022433

Sources

References

[1]
ClinicalTrials.gov — 299 trial records for Ticagrelor. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Brilinta drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Ticagrelor compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Ticagrelor. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA022433). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Brilinta. U.S. Food & Drug Administration.
[7]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Purinergic Receptor P2Y12 Negative Allosteric Modulator[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AstraZeneca

Patent Landscape[6]

Patent Cliff

Apr 17, 2030

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8425934Apr 17, 2030

8425934*PEDOct 17, 2030

10300065Jan 27, 2036

10300065*PEDJul 27, 2036

Brilinta

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Acute Coronary Syndrome22 trials

Clopidogrel13 trials

Myocardial Infarction10 trials

Coronary Artery Disease7 trials

Endothelial Function6 trials

Ischemic stroke6 trials

Stroke6 trials

Antiplatelet5 trials

Platelet Reactivity4 trials

Percutaneous Coronary Intervention4 trials

Platelet Aggregation3 trials

Injury3 trials

STEMI3 trials

Interaction3 trials

Dual Antiplatelet Therapy3 trials

Acute Myocardial Infarction3 trials

Thrombolysis3 trials

Function2 trials

Cardiac Arrest2 trials

Tics2 trials

Antithrombotic2 trials

MPA2 trials

Complication2 trials

CABG2 trials

P2Y12 Inhibitor2 trials

Pneumonia2 trials

Atrial Fibrillation2 trials

Antiplatelet Therapy2 trials

Platelet Function2 trials

Effectiveness2 trials

Coronary Artery Bypass2 trials

Abdominal Aortic Aneurysm1 trial

Diabetes1 trial

Dialysis Patients1 trial

Endothelial Dysfunction1 trial

LAM1 trial

Stent Thrombosis1 trial

Drug1 trial

Itching1 trial

Randomized Controlled Trial1 trial

Atherosclerosis1 trial

TED1 trial

Platelet Inhibition1 trial

Optical Coherence Tomography1 trial

Monotherapy1 trial

ST Elevation Myocardial Infarction1 trial

Type 2 Diabetes Mellitus1 trial

Thrombosis1 trial

Oral Anticoagulation1 trial

Chronic Kidney Disease1 trial

Age1 trial

Vascular Disease1 trial

Angina Pectoris1 trial

Aortic Stenosis1 trial

Intensive Care Unit1 trial

Arterial Stiffness1 trial

Statin1 trial

Microcirculation1 trial

Prevention1 trial

Sickle Cell Disease1 trial

Aneurysm1 trial

Intraoperative1 trial

Ischemia1 trial

Type 2 Diabetes1 trial

Oral1 trial

Infusion1 trial

RCT1 trial

Trial1 trial

Treatment1 trial

Ventricular Function1 trial

ART1 trial